key: cord-0844631-78h5zoa3
authors: Chen, Hongbo; Xie, Zhongping; Long, Runxiang; Fan, Shengtao; Li, Heng; He, Zhanlong; Xu, Kanwei; Liao, Yun; Wang, Lichun; Zhang, Ying; Li, Xueqi; Dong, Xingqi; Mou, Tangwei; Zhou, Xiaofang; Yang, Yaoyun; Guo, Lei; Yang, Jianbo; Zheng, Huiwen; Xu, Xingli; Li, Jing; Liang, Yan; Li, Dandan; Zhao, Zhimei; Hong, Chao; Zhao, Heng; Jiang, Guorun; Che, Yanchun; Yang, Fengmei; Hu, Yunguang; Wang, Xi; Pu, Jing; Ma, Kaili; Wang, Lin; Cheng, Chen; Duan, Weiguo; Shen, Dong; Zhao, Hongling; Jiang, Ruiju; Deng, Xinqiang; Li, Yan; Zhu, Hailian; Zhou, Jian; Yu, Li; Xu, Mingjue; Yang, Huijuan; Yi, Li; Zhou, Zhenxin; Yang, Jiafang; Duan, Nan; Yang, Huan; Zhao, Wangli; Yang, Wei; Li, Changgui; Liu, Longding; Li, Qihan
title: Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques
date: 2021-08-26
journal: Mol Ther Methods Clin Dev
DOI: 10.1016/j.omtm.2021.08.005
sha: 7988cba95a1704f9b2fa8cbf5a9da3aa8dedca6b
doc_id: 844631
cord_uid: 78h5zoa3

Because of the relatively limited understanding of COVID-19 pathogenesis, immunological analysis for vaccine development is needed. Mice and macaques were immunized with an inactivated SARS-CoV-2 vaccine prepared by two inactivators. Various immunological indexes were tested, and viral challenges were performed on day 7 or 150 after booster immunization in monkeys. This inactivated SARS-CoV-2 vaccine was produced by sequential inactivation with formaldehyde followed by propiolactone. The various antibody responses and specific T cell responses to different viral antigens elicited in immunized animals were maintained for longer than 150 days. This comprehensive immune response could effectively protect vaccinated macaques by inhibiting viral replication in macaques and substantially alleviating immunopathological damage, and no clinical manifestation of immunopathogenicity was observed in immunized individuals during viral challenge. This candidate inactivated vaccine was identified as being effective against SARS-CoV-2 challenge in rhesus macaques.

Because of the relatively limited understanding of COVID-19 pathogenesis, 28 immunological analysis for vaccine development is needed. Mice and macaques were 29 immunized with an inactivated SARS-CoV-2 vaccine prepared by two inactivators. 30 Various immunological indexes were tested, and viral challenges were performed on 31 day 7 or 150 after booster immunization in monkeys. This inactivated SARS-CoV-2 32 vaccine was produced by sequential inactivation with formaldehyde followed by Since the end of last year, a new species of coronavirus, a contagious agent 46 capable of causing acute and severe respiratory infection and pneumonia through 47 airborne transmission, has rapidly caused global public concern and even fear 1-3 . 48 This coronavirus was named SARS-CoV-2 by the World Health Organization (WHO) 4 . 49 Updated data indicate that more than 40 million infections have occurred worldwide 50 5 , and the mortality rate is approximately 3-10%, with most deaths occurring in the 51 elderly population 6, 7 . In this emergency pandemic situation 8-10 , vaccine 52 development is urgently needed 11, 12 . However, as SARS-CoV-2 is a new viral agent 53 with an unknown infection mechanism and an unclear interaction with the immune 54 system, the evaluation of vaccines requires a comprehensive analysis of the 55 immunological index observed in immunized animals, which involves the 56 characterization of the antigenic component of this virus and its immunogenicity, the 57 protective immunity elicited by the viral antigen via certain immune processes, the 58 period in which immunity persists, and whether the process of developing immunity 59 against a viral antigen is associated with immunopathogenesis during viral infection 60 13, 14 . Based on these considerations, the following hypothetical model was used as 61 the basis for the present study: SARS-CoV-2 infects cells via the binding of its spike (S) 62 protein to angiotensin converting enzyme 2 (ACE2) molecules on the cell membrane, 63 indicating that the S protein, particularly the receptor-binding-domain (RBD) that 64 directly interacts with ACE2, is a major viral antigen that elicits a neutralizing that was developed based on the aforementioned model, and the characterized 69 immune response revealed the various antibody responses and specific T cell 70 responses to different viral antigens that were maintained for longer than 150 days. 71 Importantly, this immune response was capable of defending against viral infection in Not only the S protein but also the N protein and other proteins were recognized by 88 the serum, as the virus was neutralized by the antibodies contained in the sample; 89 this recognition was more extensive than that observed by immune blotting with a 90 monoclonal antibody (mAb) against the S or N protein (Supplemental Fig. 1) . 91 Furthermore, a technical evaluation of the vaccine showed that an appropriate 92 J o u r n a l P r e -p r o o f 5 inactivation process enables virions to present S and N antigens. This inactivation 93 process included an initial inactivation step with formalin (1:4000) for 48 h upon 94 harvesting the virus, a purification step, and a second inactivation step with 95 beta-propiolactone (1:2000) for 48 h (Fig. 1a) . In the subsequent electronic 96 microscopic observation, the virions inactivated by the treatment with both agents 97 were simultaneously recognized by antibodies specific for N and S, but the control 98 virions inactivated by treatment with only one of the two inactivators were 99 recognized by only either the anti-S or the anti-N antibody (Fig. 1b) . These results 100 were further evaluated in immunized BALB/c mice after a single intraperitoneal 101 injection of the inactivated vaccine in gradient doses. The detection of neutralizing 102 antibodies suggested that the vaccine inactivated by treatment with both 103 inactivators elicited a higher antibody titer than the vaccines inactivated by 104 treatment with only one of the two control inactivators at each dilution of antigen 105 (Fig. 1c) . The enzyme-linked immunosorbent assay (ELISA) results indicated the 106 induction of antibodies specific for the S protein, N protein and virions (Fig. 1d) . 107 Collectively, these data support the antigenicity and immunogenicity of our 108 inactivated SARS-CoV-2 vaccine. 6 on the results, the elicited antibody response, including neutralizing antibodies and 117 specific antibodies against viral proteins in these immunized mice, presented a 118 dynamic variation and was consistently positive for up to 5 months, eliciting a T cell 119 response against the viral S or N protein or the virion at day 150 ( Fig. 2a, b, c) . 120 Increasing neutralizing antibody titers were observed on day 7 after booster 121 inoculation, with geometric mean titers (GMTs) of 107.6, 25.4 and 2 in 10 macaques 122 from group A immunized with the three doses (200, 100 and 20 ELISA units (EU), 123 respectively) on days 0 and 14 (Fig. 2d) . Moreover, titers of less than 1:4 were 124 observed in 2 macaques from the low-dose group (i.e., 20 EU). This result suggests a 125 dose dependence for immunization with this vaccine. However, ELISA with plates 126 coated with the S or N protein or the purified virion indicated no obvious differences 127 in the titers of anti-S, anti-N and anti-virion antibodies (Fig. 2e) . Furthermore, an 128 enzyme-linked immunosorbent spot (ELISPOT) analysis of IFN-γ specificity at day 7 129 post immunization showed a positive T cell response with no dose dependency after 130 stimulation with the S or N antigen (Fig. 2f ). In a further study, 18 macaques from 131 group C immunized with 100 EU/dose by the same procedure were monitored for 5 132 months and showed a dynamic trend of a neutralizing antibody response associated 133 with specific antibodies against viral proteins, which was maintained for up to 150 134 days postinfection (dpi) (Fig. 2g, (Table 1 ). The detection of viral loads indicated that viral shedding in the 151 nasal cavity, i.e., the site of viral challenge, in macaques immunized with the animals, including 5 adjuvant control-treated macaques, were examined to detect 165 viral loads and for pathological observations. Based on the q-RT-PCR results, the viral 166 genome copy numbers in almost all samples of various tissues from the macaques in 167 the vaccine immunization group were less than 50 copies/100 mg, and only the viral 168 genome copy numbers in spleens were greater than 100 copies/100 mg (Fig. 3b) . 169 Interestingly, the two macaques that were immunized with a low dosage of the 

Epidemiology of COVID-19

Central nervous system manifestations of COVID-19: A 515 systematic review

WHO International Health Regulations Emergency Committee for the COVID-19 517 outbreak

Coronavirus: Update 519 Related to the Current Outbreak of COVID-19

COVID-19 Dashboard by the Center for Systems Science 13

Is COVID-19 receiving ADE from other coronaviruses?

It is too soon to attribute ADE to COVID-19. Microbes Infect

SARS-CoV-2 Cell Entry Depends on ACE2 and 546 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Pathogen recognition by the innate immune system. immunized and challenged on day 7 after the booster immunization (groups A 671 and B)

Th17 and Treg cells among PBMCs or in lungs 673 from rhesus macaques that were immunized and challenged on day 150 after the 674 booster immunization (groups C and D)

Serum IL-2, IL-4, IL-5, IL-6 and TNF-α levels in rhesus macaques that were 676 immunized and challenged on day 150 after the booster immunization (groups C 677 and D)

The normal range (referring to the normal macaques monitored during the same 679 period) is indicated with dotted lines. Two hundred EU (n=4), 100 EU (n=3), 20 EU 680 (n=3) and Con (n=10) challenged on day 7 after the booster

Con (n=12) challenged on day 150 after the booster. The results are presented as

This study was supported by grants from the National Key R&D Program of China 494 (2020YFC0849700 and 2020YFC0860600) and Major Science and Technology Special